Natalia Tamara Santis

Prof. Natalia Tamara Santis

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EJEduardo Felipe Durán Jara
Eduardo Felipe Durán Jara
IPIván Ponce
Iván Ponce
MHMarcelo Rojas Herrera
Marcelo Rojas Herrera
JTJessica Toro
Jessica Toro
PCPaulo Covarrubias
Paulo Covarrubias
JFJorge Fernández
Jorge Fernández
Massively parallel or next-generation sequencing (NGS) has enabled the genetic characterization of cancer patients, allowing the identification of somatic and germline variants associated with their diagnosis, tumor classification, and therapy response. Despite its benefits, NGS testing is not yet available in the Chilean public health system, rendering it both costly and time-consuming for patients and clinicians. Using a retrospective cohort of 67 formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) samples, we aimed to implement the identification, annotation, and prioritization of relevant actionable tumor somatic variants in our laboratory, as part of the public health system. We compared two different library preparation methodologies (amplicon-based and capture-based) and different bioinformatics pipelines for sequencing analysis to assess advantages and disadvantages of each one. We obtained 80.5% concordance between actionable variants detected in our analysis and those obtained in the Cancer Genomics Laboratory from the Universidad de Chile (62 out of 77 variants), a validated laboratory for this methodology. Notably, 98.4% (61 out of 62) of variants detected previously by the validated laboratory were also identified in our analysis. Then, comparing the hybridization capture-based library preparation methodology with the amplicon-based strategy, we found ~94% concordance between identified actionable variants across the 15 shared genes, analyzed by the TumorSecTM bioinformatics pipeline, developed by the Cancer Genomics Laboratory. Our results demonstrate that it is entirely viable to implement an NGS-based analysis of actionable variant identification and prioritization in cancer samples in our laboratory, being part of the Chilean public health system and paving the way to improve the access to such analyses. Considering the economic realities of most Latin American countries, using a small NGS panel, such as TumorSecTM, focused on relevant variants of the Chilean and Latin American population is a cost-effective approach to extensive global NGS panels. Furthermore, the incorporation of automated bioinformatics analysis in this streamlined assay holds the potential of facilitating the implementation of precision medicine in this geographic region, which aims to greatly support personalized treatment of cancer patients in Chile.

15 August 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
Diego A. Diaz-DinamarcaDiego A. Diaz-Dinamarca
Diego A. Diaz-Dinamarca
SCSimone Cárdenas-Cáceres
Simone Cárdenas-Cáceres
NMNicolas Alvaro Muena
Nicolas Alvaro Muena
PDPablo Andres Diaz
Pablo Andres Diaz
GBGisselle Barra
Gisselle Barra
AVAbel Vasquez
Abel Vasquez
The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are the main vaccines used in Chile. Much less is known about the Wuhan-Hu-1 strain-based vaccines in the pediatric population compared to adults. Given the worldwide need for booster vaccinations to stimulate the immune response against new Omicron variants of SARS-CoV-2, we characterized the humoral and cellular immune response against Omicron variant BA.1 in a pediatric cohort aged 10 to 16 years who received heterologous vaccination based on two doses of CoronaVac, two doses of CoronaVac (2x) plus one booster dose of BNT162b2 [CoronaVac(2x) + BNT162b2 (1x)], two doses of CoronaVac plus two booster doses of BNT162b2 [CoronaVac(2x) + BNT162b2 (2x)], and three doses of BNT162b2. We observed that the [CoronaVac(2x) + BNT162b2 (2x)] vaccination showed higher anti-S1 and neutralizing antibody titers and CD4 and CD8 T cell immunity specific to the Omicron variant compared to immunization with two doses of CoronaVac alone. Furthermore, from all groups tested, immunity against Omicron was highest in individuals who received three doses of BNT162b2. We conclude that booster vaccination with BNT162b2, compared to two doses of CoronaVac alone, induces a greater protective immunity.

27 December 2024 in Journal of Migration and Health
Verified
Journal Article
Open access
Rodrigo PuentesRodrigo Puentes
Rodrigo Puentes
MDMaría Alejandra Dünner
María Alejandra Dünner
NSNatalia Tamara Santis
Natalia Tamara Santis
MSMario E. Soto-Marchant
Mario E. Soto-Marchant
CCCecilia Canales
Cecilia Canales
JDJanepsy Díaz
Janepsy Díaz
International migrants are central to HIV research, but comparative data on their infection rates versus resident populations, including in Chile, are scarce. This study compares HIV incidence rates between international migrants and Chileans. A longitudinal study was conducted. Crude and standardized rates of new HIV infections reported by the Institute of Public Health of Chile (ISP) were calculated for the period 2013 to 2022, using data from public and private health facilities nationwide. Population estimates for international migrants and Chileans were obtained from the National Institute of Statistics (INE) and the National Migration Service (SERMIG). Rates were adjusted for age and sex using the direct method. A total of 51,513 validated new HIV infections were analyzed, of which 14,936 (29.0 %) occurred in international migrants and 36,577 (71.0 %) in Chileans. International migrants showed an increase in incidence rates between 2013 and 2022 (adjusted rate from 22.6 [95 % CI: 18.3 – 27.0] to 115.6 [95 % CI: 110.5 – 120.7] new HIV infections per 100,000 population). Throughout the study period, the ratio of adjusted incidence rates between international migrants and Chileans increased from 1.0 [95 % CI: 0.9 – 1.2] to 7.6 [95 % CI: 7.2 – 8.0]. HIV incidence rates were higher in international migrants than in Chileans and increased over the study period. This may be influenced by various exogenous factors, including social determinants of health and the COVID-19 pandemic. It is crucial to focus on HIV diagnosis, prevention, and control strategies for international migrants in Chile.

9 February 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Diego A. Diaz-DinamarcaDiego A. Diaz-Dinamarca
Diego A. Diaz-Dinamarca
SCSimone Cárdenas-Cáceres
Simone Cárdenas-Cáceres
NMNicolas Alvaro Muena
Nicolas Alvaro Muena
PDPablo Andres Diaz
Pablo Andres Diaz
GBGisselle Barra
Gisselle Barra
AVAbel Vasquez
Abel Vasquez
The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19—associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are among the top most widely used COVID-19 vaccines. Much less is known on the Wuhan-Hu-1 strain based vaccines in the pediatric population compared to adults. Given the worldwide need for booster vaccinations to stimulate the immune response against new Omicron variants of SARS-CoV-2, we characterized the humoral and cellular immune response against Omicron variant BA.1 in a pediatric population aged 10 to 16 years who received heterologous vaccination based on two doses CoronaVac, two doses CoronaVac (2x) plus one booster doses BNT162b2 [CoronaVac(2x) + BNT162b2 (1x)], two doses CoronaVac plus two booster doses BNT162b2 [CoronaVac(2x) + BNT162b2 (2x)], and three doses BNT162b2. We observed that [CoronaVac(2x) + BNT162b2 (2x)] vaccination showed higher anti-S1 and neutralizing antibody titers and CD4 and CD8 T cell immunity specific to the Omicron variant compared to immunization with two doses CoronaVac alone. Furthermore, from all groups tested, immunity against Omicron was highest in individuals who received three doses BNT162b2. We conclude that booster vaccination with BNT162b2 promotes greater immunity against SARS-CoV-2 in the pediatric population compared to two doses CoronaVac alone.

10 July 2026 in Journal of Cancer Policy
Verified
Journal Article
Closed access
NBNicole Bruneau
Nicole Bruneau
MBMonserrat Balanda
Monserrat Balanda
HMHéctor San Martín
Héctor San Martín
TMTamara Muñoz
Tamara Muñoz
FRFrancisco Roldán
Francisco Roldán
EREugenio Ramírez
Eugenio Ramírez